What Has Been The Evolution of the Oral Thin Films Market in Recent Years?
The oral thin films market has seen considerable growth due to a variety of factors.
• In recent times, there has been a significant expansion in the size of the oral thin films market. Its value is anticipated to surge from $4.48 billion in 2024, reaching $5.03 billion in 2025, signifying a compound annual growth rate (CAGR) of 12.2%.
The surge in growth during the historical period could be ascribed to factors such as patient compliance, suitability for pediatric and geriatric patients, faster drug delivery, chronic illnesses, and the prevalence of over-the-counter (OTC) medications.
What Is the Forecasted Market Size and Growth Rate for The Oral Thin Films Market?
The oral thin films market is expected to maintain its strong growth trajectory in upcoming years.
• The market size of oral thin films is predicted to experience a swift expansion in the approaching years, as it's projected to reach a value of $8.72 billion in 2029, with a compound annual growth rate (CAGR) of 14.7%.
The surge during the forecasted period is anticipated to be driven by factors like specialty pharmaceuticals, precision medicine, mental health medications, oral vaccines, and telemedicine services. Moreover, the prediction for the forecast period features trends like drug delivery technologies, remote healthcare, enhancement of bioavailability, usage during travel and on-the-move, and formulations free from allergens.
Which Factors Are Boosting Growth In The Oral Thin Films Market?
The surge in the demand for thin film drug delivery systems is spurring the expansion of the oral thin film market. Thin films are being recognized as a promising substitute to conventional dosage forms. They serve as an easy-to-use, quick dissolving and self-administered dosage form for medication delivery, thus making them a flexible drug delivery system. Thin films, consumed orally, eliminate the need for water for drug absorption. Due to their high dissolution rate, oral thin films are preferred by patients, hence increasing the demand for thin-film drug delivery systems. More than half of the US population is affected by cardiovascular disease. A report by The American Cancer Society, a US-based non-profit organization, in January 2023 stated that at least 42% of new cancer cases in the US, excluding non-melanoma skin cancer, accounted for around 820,000 cases in 2023 and 840,000 cases in 2024. This underscores the escalating need for innovative drug delivery methods for efficient treatment. Consequently, the escalating demand for thin film drug delivery systems is stimulating the growth of the oral thin film market.
What Key Areas Define The Segmentation Of The Global Oral Thin Films Market?
The oral thin films market covered in this report is segmented –
1) By Type: Sublingual Film, Fast Dissolving Dental/Buccal Film
2) By Disease Indication: Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting, Other Disease Indication
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Sublingual Film: Drug Delivery Films, Nutritional Supplement Films
2) By Fast Dissolving Dental Or Buccal Film: Over-the-Counter (OTC) Products, Prescription Products
Pre-Book The Oral Thin Films Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Oral Thin Films Market?
Leading firms in the oral thin films market, such as Rizaport, are driving their revenues by developing innovative products. Rizaport, a registered oral thin-film formulation, contains rizatriptan benzoate which is an agonist of the 5-HT1 receptor and the active component of Maxalt by Merck & Co. In February 2024, the oral thin film technology was introduced by CD Formulation, a drug formulation company based in the US. This technology, which is user-friendly especially for those who have trouble swallowing, dissolves in the oral cavity ensuring fast absorption and bypasses the digestive system for quicker action. This groundbreaking drug delivery method boosts bioavailability, offers accurate dosage for personalized treatment, and enhances convenience and medication compliance, particularly in emergency scenarios.
Who Are the Key Players in the Oral Thin Films Market?
Major companies operating in the oral thin films market include:
• ZIM Laboratories Limited
• NAL Pharma
• Cure Pharmaceutical Holding Corp.
• IntelGenx Corp.
• Kyu Kyu Pharmaceutical Co. Ltd.
• Sunovion Pharmaceuticals Inc.
• Seoul Pharma Co. Ltd.
• Aquestive Therapeutics Inc.
• Shilpa Therapeutics Pvt. Ltd.
• Mylan Inc.
• LIVKON Pharmaceuticals Pvt. Ltd.
• Panacea Biotec Ltd.
• Adare Pharmaceuticals Inc.
• APR Applied Pharma Research SA
• BioDelivery Sciences International Inc.
• Sumitomo Dainippon Pharma Co. Ltd.
• Indivior PLC
• LTS Lohmann Therapie-Systeme AG
• Tesa Labtec GmbH
• Pfizer Inc.
• Sanofi S.A.
• Merck & Co. Inc.
• Novartis International AG
• Roche Holding AG
• Johnson & Johnson
• GlaxoSmithKline plc
• Bayer AG
• Eli Lilly and Company
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Novo Nordisk A/S
• AstraZeneca plc
What Is The Most Dominant Region In The Oral Thin Films Market?
North America was the largest region in the oral thin film market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral thin films market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
